Parvolex Disease Interactions

The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.

Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm. Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.

Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death. To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).

The use of acetylcysteine may worsen vomiting. Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage. In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.